Most preclinical therapeutic studies of microRNAs (miRs) and small interfering (si)RNAs have provided "proof of principle" that upon ex vivo transfection of cancer cells, a therapeutic effect can be obtained. [1] [2] [3] We previously demonstrated that the need to transfect could potentially be overcome by using miR to directly modulate the immune system and initiate antitumor cytotoxicity. 4 Malignant cells express various antigens recognized by the immune system, but antitumor cytotoxicity is restrained by signal transducer and activator of transcription 3 (STAT3) signaling. [5] [6] [7] [8] We have identified miR-124 as a key regulator of the STAT3 pathway and shown that systemically administered miR-124 has marked therapeutic effects in preclinical malignancy models, including in established, heterogeneous, highgrade, genetically engineered murine models during late stages of gliomagenesis. 4 These therapeutic effects encompass marked enhancement of antitumor immunity, including interferon (IFN)-γ responses, and reversal of tumor-mediated immunosuppression. 4 
Most preclinical therapeutic studies of microRNAs (miRs) and small interfering (si)RNAs have provided "proof of principle" that upon ex vivo transfection of cancer cells, a therapeutic effect can be obtained. [1] [2] [3] We previously demonstrated that the need to transfect could potentially be overcome by using miR to directly modulate the immune system and initiate antitumor cytotoxicity. 4 Malignant cells express various antigens recognized by the immune system, but antitumor cytotoxicity is restrained by signal transducer and activator of transcription 3 (STAT3) signaling. [5] [6] [7] [8] We have identified miR-124 as a key regulator of the STAT3 pathway and shown that systemically administered miR-124 has marked therapeutic effects in preclinical malignancy models, including in established, heterogeneous, highgrade, genetically engineered murine models during late stages of gliomagenesis. 4 These therapeutic effects encompass marked enhancement of antitumor immunity, including interferon (IFN)-γ responses, and reversal of tumor-mediated immunosuppression. 4, 9 Although the preclinical data for miR-124 were promising when using Lipofectamine as a delivery vehicle, a major hurdle to its clinical translation is an appropriate drug formulation and optimization. Intravenous delivery is ideal, given its ease of administration, and is theoretically advantageous over other routes because circulating immune cells are the first point of contact with i.v. administered miRs. When encapsulated in nanoparticles, miRs can be stabilized and further targeted to the peripheral blood mononuclear cells (PBMCs)/immune compartment. Here we describe a clinically relevant formulation of miR-124 encapsulated in lipid nanoparticles (LNPs) that demonstrates marked improvements over the prior state-of-theart therapeutic efficacy, immune compartment delivery, and immunomodulation (relative to a Lipofectaminebased formulation) which is also able to prevent tumor recurrence.
Materials and Methods

Preparation of siRNA Nanoparticles
Using a proprietary bilipid delivery technology platform, LUNAR technology, Arcturus Therapeutics created 4 test articles containing miR-124: NB5-55-1, NB5-55-2 (designated LUNAR-301), NB5-55-3, and NB5-55-4. The LNPs were prepared by mixing appropriate volumes of lipids in ethanol with an aqueous phase containing miR duplexes, employing a Nanoessembler microfluidic device, followed by downstream processing as described in the Supplementary Materials and Methods. The mol% ratio for the constituent lipids was 58% ATX (proprietary ionizable amino lipids), 7% DSPC (1,2-dioctadecanoylsn-glycero-3-phosphocholine), 33.5% cholesterol, and 1.5% DMG-PEG (1,2-Dimyristoyl-sn-glycerol, methoxypolyethylene glycol, PEG chain molecular weight: 2000). Particle size was determined by dynamic light scattering (ZEN3600, Malvern Instruments). Nanoparticle formulations were compared against the prior state-of-the-art delivery of miR-124 with Lipofectamine 2000 (abbreviated as Lipofectamine in the text afterward), which used 20 µg of the miR-124 duplex in 10 µL of phosphate buffered saline (PBS) mixed with the delivery vector (80 µL PBS containing 10 µL Lipofectamine). The miR-124 duplex used for all formulations was based on pre-miR-124a (sense: 5ʹ-UAAGGCACGCGGUGAAUGCCA-3ʹ, antisense: 3ʹ-UAAUUCCGUGCGCCACUUACG-5ʹ), which was synthesized by Avetra Bioscience. 
In vitro Cell Viability Assay
In vivo Murine Tumor Models
All animal experiments were conducted in compliance with the guidelines for animal care and use established by the University of Texas MD Anderson Cancer Center under protocol 08-12-09031 (00001176-RN00). Details regarding the GL261 and B16 murine models are provided in the Supplementary Materials and Methods. Mice were randomly assigned to control or treatment groups (n = 6-10/ group) 3 days post tumor implantation for intracerebral models and 2 weeks for subcutaneous models. The animals with intracerebral tumors were treated intravenously for 3 weeks; thereafter the final endpoint was survival. Mice with subcutaneous tumors were treated for 2 weeks. Treatment groups included: miR-124 in combination with Lipofectamine and miR-124 in LUNAR nanoparticles (NB5-55-1, NB5-55-2 [also designated LUNAR-301], NB5-55-3, and NB5-55-4). All animals were treated at a dose of 1mg/ kg administered Monday, Wednesday, and Friday. A supplementary study was conducted to evaluate LUNAR-301 dosing at 2.5mg/kg on a different treatment schedule (Monday and Thursday administration). To determine whether immunological memory was induced, surviving mice were rechallenged by implanting 5×10 4 GL261 glioma cells intracerebrally in the contralateral hemisphere. Mice were subsequently observed for continued survival.
Murine Pharmacokinetic Analysis
The pharmacokinetics of LUNAR-301 in vivo were compared with those of miR-124 + Lipofectamine in
Importance of the study
For the first time, we are showing the unique application of microRNAs delivered in nanoparticles as novel immune therapeutics for the treatment of malignancy. Although we show this in the context of gliomas, this therapeutic approach would be widely applicable to any type of hematopoietic or solid malignancy. Specifically, we use lipid nanoparticles to deliver miR-124, which targets a tumor-mediated immune suppressive hub-the signal transducer and activator of transcription 3-to very high levels in the immune compartment in vivo. This therapeutic approach stimulates antitumor immune responses without significant toxicity, significantly prolongs survival in murine intracerebral glioma models, and induces immunological memory that is protective of tumor rechallenge. Its safety and immune activating property are further validated in a canine model. Finally, of more global importance, conventional immunotherapeutics have been limited to surface targets-a barrier we have overcome using nanoparticles that can target intracellular pathways.
non-tumor-bearing C57BL/6 mice at a 1mg/kg i.v. dose. The mice (n = 3/group/time point) were treated once and subsequently terminated at 0 minutes, 15 minutes, and at 1, 4, 8, and 24 hours post delivery. At each time, the serum, liver, and PBMCs were sampled for total RNA extraction. The miR-124 concentration in each compartment was assessed by quantitative real-time (RT)-PCR using a standard curve containing a series of miR-124 duplex dilutions. A noncompartmental analysis was performed in mice using industry-standard software (WinNonLin 6.3, Pharsight) to estimate the pharmacokinetic parameters as further described in the Supplementary Materials and Methods for each individual animal, using drug concentrations observed in serum, liver, and PBMCs.
Murine Immune Functional Studies
C57BL/6 mice were subcutaneously implanted with 2×10 6 GL261 cells in Matrigel to have a tumor sufficiently large for analysis of the infiltrating immune population. Two weeks after implantation, mice were randomized by tumor size and treated with empty nanoparticles, miR-124 + Lipofectamine, or LUNAR-301 (n = 3-4 per group) for 5 doses on Monday, Wednesday, and Friday at 1mg/ kg. The control group of mice was untreated (n = 5). For glioma-infiltrating T-cell isolation, subcutaneous gliomas were homogenized in cold MACS buffer (1× PBS, 2% fetal bovine serum, 2mM EDTA) to make a single-cell suspension. Splenocytes were also harvested and homogenized in cold MACS buffer. Red blood cells were removed with red blood cell-lysing buffer (Sigma-Aldrich) to form a single-cell suspension of splenocytes that were cocultured with Dynabeads CD3/CD28 (Life Technologies) and supplemental interleukin (IL)-2 for 7 days to activate T cells. For intracellular phosphorylated (p)STAT3 and FoxP3 detection, glioma-infiltrating T cells were fixed and permeabilized (eBioscience) for 1 hour at 4°C. Cells were then stained with phycoerythrin (PE)-conjugated anti-STAT3 (Y705) antibody (eBioscience) or PE-conjugated anti-FoxP3 antibody (eBioscience) for 30 minutes at 4°C. Flow cytometry acquisition was performed with fluorescence activated cell sorting (FACSCalibur, Becton Dickinson), and data were analyzed using FlowJo software (TreeStar).
Murine Toxicity Study
Non-tumor-bearing C56BL/6 mice were dosed with LUNAR-301 or empty nanoparticles at 1mg/kg Monday, Wednesday, and Friday for 3 weeks (n = 8 per group). A control group of mice remained untreated (n = 8). Toxicity to mice was monitored on a regular schedule, evaluating weight and neurological status. After completion of the treatment regimen, mice were euthanized, and organs including the spleen, thymus, lungs, heart, kidneys, brain, liver, and gastrointestinal tract were harvested, formalin fixed, and cryotome sectioned. Tissue sections were stained using hematoxylin and eosin. A pathologist who was blinded to the treatment regimen performed the histologic examination (Dr David Calise). Additional toxicity studies are described in the Supplementary Materials and Methods.
Canine Model
Purpose-bred beagles (n = 5) were utilized for a secondspecies analysis. A dose escalation starting at 0.25mg/kg was selected using an allometric scaling calculator and derived from the effective therapeutic dose (1mg/kg) in glioma-bearing mice. Blood samples (3mL) for analysis of the miR-124 concentration in serum and in PBMCs were collected at 10, 20, 30, 45, and 60 minutes, and at 2, 4, 6, 12, 24, 48, and 72 hours post-LUNAR-301 delivery. Immune activation status was sampled at 0 and 24 hours. At 72 hours, blood was obtained for complete blood count, serum chemistry profile, and the coagulation profile. RT-PCR was used to quantify miR-124 in canine PBMCs and serum as previously described. 4 LUNAR-301 and empty nanoparticle administration (i.v.) was through the cephalic vein. Canines were subsequently euthanized and received a complete necropsy, with gross and histological examination as described further in the Supplementary Materials and Methods.
Canine Flow Cytometry
Details are provided in the Supplementary Materials and Methods, but briefly PBMCs were stained with 1:30 antimouse/rat FoxP3 APC (eBioscience) or with 1:100 canine biotin-conjugated IL-2, IFN-γ, or tumor necrosis factor (TNF)-α (RD Systems).
Statistical Analysis
For comparison of serum cytokines and to produce a more Gaussian data distribution, all P-values were calculated using linear regression after Box-Cox transformation (with parameters λ 1 = 0 and λ 2 = 1 to convert the right-skewed data so that it follows a normal distribution) and adjusted by Holm's approach. 10 Overall survival (OS), defined as the time (in days) from the day of tumor cell implantation to the date of death, was estimated using the method of Kaplan and Meier. 11 The log-rank test 12 and Cox proportional hazards regression model were used to explore the survival differences between individual treatment groups. 13 The one-sided Fisher's exact test was used to compare the cure rates for LUNAR-301 with those of other treatment groups. Given the linearity in the plot of log(-log(Kaplan-Meier survival estimate)) versus log(survival time) for each treatment group, the OS time between control and LUNAR-301 groups was assessed using a Weibull accelerated failure time model. A longitudinal linear mixed effects regression model was employed to estimate the tumor growth rate after the logarithmic transformation of tumor volume. Statistical software R V-3.1.2 (with packages survival v2.38-1 and nlme v3.1-120) was used for data analysis. P ≤ .05 was considered statistically significant.
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Results
Therapeutic Efficacy of Lipid Nanoparticles Containing MiR-124
MiR-124 was encapsulated in LNPs with an efficiency of >95% and a polydispersity index of <0.05 using a good manufacturing practice-ready process of a Nanoessembler microfluidic device, followed by downstream processing. This produced an 80nm particle with long-term stability (>4 mo) and little variation in particle size (Fig. S1A ). Four test articles (miR-124 nanoparticles) with modifications of the lipid formulation were devised. Therapeutic equivalency studies were conducted at a dose of 1mg/kg on a Monday, Wednesday, and Friday dosing schedule in C57BL/6 mice with intracerebral GL261 gliomas. Of the test articles, NB5-55-2 (renamed LUNAR-301) demonstrated superiority, with a median survival time that could not be calculated because >60% of mice were long-term survivors. The 3 remaining miR-124 nanoparticle formulations produced median survivals of 30.5, 43.5, and 6 days for NB5-55-1, NB5-55-3, and NB5-55-4, respectively ( Fig. 1 ) (Lipofectamine control group: 40 days). Significant toxicity was observed in the NB5-55-4 group, and necropsy showed that the deaths did not result from intracranial tumors.
To determine whether dose or frequency of drug administration could improve efficacy, LUNAR-301 (1mg or 2.5mg/ kg) was evaluated on a Monday and Thursday treatment schedule. Mice with intracerebral GL261 gliomas were treated, and survival was compared with the traditional dosing schedule of Monday, Wednesday, and Friday (1mg/ kg miR-124 + Lipofectamine), with all mice being treated for 3 weeks. LUNAR-301 at 1mg/kg performed similarly to miR-124 + Lipofectamine at 1mg/kg (median survival times for the 2 groups: 32.5 and 31.5 days, respectively, with no significant difference, P = 0.813). Mice treated with LUNAR-301 at 2.5mg/kg showed a median survival time (27 days) comparable to and not significantly different from controls: Lipofectamine alone and empty nanoparticles (22 days [P = 0.930] and 24 days [P = 0.904], respectively) (Fig. S1B) . Because an increase in the dose and a decrease in the frequency did not improve the therapeutic outcome, we established the therapeutic dose and schedule of LUNAR-301 to be 1mg/kg on Monday, Wednesday, and Friday for 3 weeks. LUNAR-301 also exerted a therapeutic effect in other immune competent models of malignancy (Fig. S2 ).
Lipid Nanoparticles Target the Immune Compartment
To ascertain the kinetics and concentrations of miR-124 within the PBMCs after LUNAR-301 treatment, non-tumorbearing C57BL/6 mice were dosed once with LUNAR-301 at Fig. 1 Screening of nanoparticle formulations of miR-124. The treatment schema (A) and survival (B) of 4 lipid-based nanoparticle formulations encapsulating miR-124 tested in the same murine GL261 glioma model. Of the test articles prepared, NB5-55-2 (LUNAR-301) showed the greatest therapeutic effect relative to Lipofectamine, producing a median survival time that could not be calculated because >60% of mice were long-term survivors; n = 6 mice per treatment group. MiR-124 + Lipofectamine, the prior state-of-the-art combination, is used as the control. This experiment was repeated with LUNAR-301 with similar superior outcome.
1mg/kg and compared with miR-124 + Lipofectamine. The serum, liver, and PBMCs were examined by quantitative RT-PCR to assess the miR-124 level in each compartment. At all time points and compartments, LUNAR-301 achieved higher concentrations of miR-124 than were delivered with Lipofectamine ( Fig. 2A) . Due to reticuloendothelial system clearance, as expected, greater retention of miR-124 was measured in the liver with LUNAR-301. MiR-124 kinetics were analyzed in the PBMC compartment, which is the desired delivery compartment (ie, immune cells). After a single dose, peak concentrations were achieved at 15 minutes, and miR-124 persisted for >24 hours (Table S1 and Table  S2 ). We then fractionated the PBMC immune subsets, analyzed the delivery of miR-124, and found that LUNAR-301 preferentially targeted monocytes, as denoted by CD11b+ (Fig. 2B) . Consistent with their biological function of endocytosis, monocytes represent an important site of STAT3 regulation, given the innate monocyte/macrophage interface with the adaptive immune responses. Additionally, we assessed whether LUNAR-301 has direct antitumor effect on glioma cells. GL261 and glioma stem cells in co-culture experiments with LUNAR-301 at in vivo physiological concentrations failed to demonstrate any direct cytotoxicity (Fig.  S3) . To verify that LUNAR-301 maintains the immunomodulatory properties documented for miR-124 + Lipofectamine, in vivo immune functional studies were performed. C57BL/6 mice were subcutaneously implanted with GL261 cells (to achieve sufficient tumor volume to analyze) and were then treated with miR-124 + Lipofectamine or LUNAR-301 for 5 doses. Thereafter, glioma-infiltrating T cells were isolated , and monocytes/macrophages (CD11b+) were then sorted by flow cytometry into subset populations, and the amount of miR-124 within each population was quantified by PCR. Compared with untreated control mice, the delivery of miR-124 was highest in the monocyte/macrophage population, and second highest in the B cells. (C) To assess the immunomodulatory properties of LUNAR-301, C57BL/6 mice with subcutaneously implanted GL261 gliomas were treated 5 times with either miR-124 + Lipofectamine or LUNAR-301. Thereafter, the glioma-infiltrating T cells were isolated and assessed for intracellular pSTAT3 and FoxP3. Phosphorylated STAT3 and FoxP3 levels were significantly lower after treatment with miR-124 + Lipofectamine (**P = .0032 and *P = .0213, respectively) and LUNAR-301 (**P = .0001 and *P = .0223, respectively) relative to the untreated group. The 2-sample t-test was used for pairwise comparison. Error bars, mean ± SD; n = 3-4 mice per treatment group. Untreated mice and mice receiving empty nanoparticles are the controls.
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and assessed for intracellular pSTAT3 and FoxP3 (Fig. 2C ). Significant reductions in pSTAT3 and FoxP3 were observed with both miR-124 + Lipofectamine (P = .0032 and P = .0213, respectively) and LUNAR-301 (P = .0001 and P = .0223, respectively) compared with the untreated group.
Immune Modulatory Nanoparticles Induce Immunological Memory
To ascertain if LUNAR-301 could protect against tumor recurrence, mice surviving an initial intracerebral GL261 glioma implantation after treatment with miR-124 + Lipofectamine or LUNAR-301 were rechallenged with a second intracerebral glioma implanted in the contralateral hemisphere, with no further treatment (Fig. 3A) . Subsequently, only one mouse died in the LUNAR-301 group (survival >200 days post initial tumor implantation; P = .005 relative to the empty nanoparticle control). Finding of fewer survivors in the miR-124 + Lipofectamine group was found to be consistent with the pharmacokinetic data. These mice were again rechallenged with a third intracerebral tumor, with no subsequent treatment with LUNAR-301; 3 of 4 of the previously treated mice Mice initially implanted with gliomas (n = 9-10 mice/group) who survived for more than 70 days after intracerebral implantation were rechallenged with gliomas implanted in the contralateral brain. These mice had been previously treated with therapeutic doses of miR-124 + Lipofectamine and LUNAR-301 (n = 2 and n = 5, respectively). On day 74, they were reimplanted with tumors, and survival was monitored; they received no further treatment. All but one mouse in the LUNAR-301 group was still alive and healthy at 200+ days after initial intracerebral implantation. (C) Long-term surviving rechallenged mice in Fig. 2B were subsequently rechallenged a third time with intracerebrally implanted gliomas in the original brain hemisphere, again with no further treatment. All but one of the mice previously treated with LUNAR-301 were protected from tumor recurrence, and the mouse that had a recurrence survived for longer than the median survival time of untreated control mice (33 days).
again survived (Fig. 3B) , indicating induction of immunological memory. Of note, immune memory is not a general property of anti-STAT3 agents, because we have previously found that small molecular inhibitors of STAT3 do not generate immunological memory in murine melanoma models.
Nanoparticle Safety Profile and Nonspecific Immune Activation
Next, we assessed safety by treating non-tumor-bearing mice for 2 weeks with either LUNAR-301 or empty nanoparticles, followed by necropsy. Microscopic analysis of the spleen, thymus, lungs, heart, kidneys, brain, liver, and gastrointestinal tract showed no treatment-related abnormalities. Sporadic vascular/perivascular inflammation was observed in the lungs, probably from foreign-body (ie, hair) injection during i.v. administration. Additional murine toxicity studies conducted by a contract research organization (BTS Research) found that a single i.v. administration of empty lipid nanoparticles at doses up to 30mg/kg was well tolerated, with no unusual observations in either sex. Clinical chemistry and hematologic analysis revealed a few significant intergroup differences; however, these were not dose related and/or were numerically close to control values.
To further verify that the immune activation resulted from miR-124 rather than being nonspecific, and to function as a more rigorous control for the toxicity studies, seed sequence modifications were made at the 5ʹ end of miR-124. Specifically, the sequence of miR-124, 5ʹ-U AAGGCACGCGGUGAAUGCCA-3ʹ, was modified to 5ʹ-U GGCAAACGCGGUGAAUGCCA-3ʹ, disrupting the miR's activity and STAT3 inhibition, but also leaving the nucleotides outside of the seed sequence intact and keeping the base composition the same. The seed sequence modification was packaged in the LUNAR nanoparticle formulation and designated seed sequence control (SSC), which was verified to not exert any therapeutic activity in mice harboring intracerebral GL261 tumors (median survival, 16 days). To assess toxicity, nontumor-bearing C57BL/6J mice (n = 5-6 per group) were dosed with LUNAR-301 (1mg/kg), SSC (1mg/kg), or i.v. PBS for 3 weeks on a Monday, Wednesday, and Friday schedule. Five hours after the ninth dose, animals were terminated, their spleens and livers examined, and sera assessed for nonspecific immune activation (ie, cytokine storm). Body weights were maintained throughout dosing (Fig. 4A) , but the liver weights of the LUNAR-301-treated group were found to be modestly increased (Fig. 4B) , along with aspartate aminotransferase (AST) levels (Fig. 4C ), but to levels significantly less than those seen in other industry standards of nanoparticle therapeutics. Relative to PBS controls, nonspecific immune activation was not triggered with the LUNAR nanoparticles, as detected by serum cytokine analysis, with the sole exceptions of granulocyte colony stimulating factor with LUNAR-301 (P = 0; ninth dose), monocyte chemoattractant protein 1 (MCP-1) with LUNAR-301 (P = .009; first dose), and MCP-1 with SSC (P = 0.04; first dose) (Fig. S4) .
Second Species Toxicity Evaluation
To test LUNAR-301 in a second species, purpose-bred non-tumor-bearing beagles were utilized. Single-dose Fig. 4 LUNAR-301 has a favorable safety profile. (A) Non-tumorbearing C57BL/6 mice were treated with either LUNAR-301 (LUN), seed sequence control (SSC), or PBS for a total of 9 doses. Their body weights were measured throughout the course of treatment, and their growth rates did not differ among treatment groups (P = .163) using random effect ANOVA. Error bars, mean ± SD. (B) At the conclusion of the study, liver and spleen weights were measured. A modest but statistically significant increase in liver weight was found in the LUNAR-301-treated mice relative to the SSC-treated (P = .018) and PBS-treated (P = .014) groups. Linear regression was used for comparison of LUNAR-301 with other treatments. Each box-whisker plot represents 5-6 mice per treatment arm. (C) Just before the final (ninth) dose, serum was collected from all mice, liver function tests (LFTs) were performed, and aspartate aminotransferase (AST) was found to be modestly elevated in the LUNAR-301 group relative to the SSC (P = .007) and PBS (P = .012) groups (ALT = alanine aminotransferase). Linear regression was used for comparison of LUNAR-301 with other treatments after logarithmic transformation to convert the data to a normal distribution. Each box-whisker plot represents 5-6 mice per treatment arm.
Yaghi et al. Therapeutic immune modulatory nanoparticles
NeuroOncology escalations (0.25, 0.5, and 1mg/kg, i.v.) and multidosing (0.5mg/kg × 9 doses) were conducted with LUNAR-301. Pre-delivery (0h) physical exams were normal in all dogs and were not altered post administration. Occasionally, mild sedation and emesis were observed (Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Event: grade I) that were not dose related. No abnormalities attributable to drug formulation or dosage were observed on complete blood counts or chemistry panels or in blood coagulation. Mild clinically insignificant fibrinogen elevation was seen with repeated sampling, probably owing to multiple blood draws. During necropsy, microscopic evaluation of organs revealed no significant abnormalities except in one dog receiving empty nanoparticles, who had a probably incidental mild multifocal lymphoplasmacytic choroid plexitis.
The distribution of miR-124 delivered by LUNAR-301 in canines was determined longitudinally in the PBMC and serum compartments using quantitative RT-PCR. The range of miR-124 levels in the immune compartment at the peak distribution period (20 minutes post infusion) ranged between 1.96 to 9.56×10 6 fold above pretreatment baselines among all canines. There was no direct linear relationship between administered dose of LUNAR-301 and delivery concentration of miR-124 in individual dogs over the small range tested (Fig. 5A) . However, during multidosing of LUNAR-301, miR-124 appeared to accumulate in the PBMC compartment (Fig. 5B) . Flow cytometry of the target immune cells demonstrated, with the exception of dose 7 in the multidose treatment, a dose-dependent response of IL-2, TNF-α, and IFN-γ effector cytokines, intracellularly, after LUNAR-301 treatment (Fig. 5C ).
Discussion
Use of miRs as a therapeutic is very appealing owing to robust preclinical data demonstrating their therapeutic efficacy, broad biological activity, and ability to shut Expanding to a second model system, we utilized purpose-bred non-tumor-bearing beagles (n = 5). Canines were treated with a single escalating dose of LUNAR-301 (301) or with 9 doses at 0.5mg/kg. Blood samples were drawn pretreatment and at various time points up to 72 hours posttreatment. (A) Serum and PBMCs were isolated, and miR-124 was quantified by PCR for each compartment. In all cases, miR-124 was elevated in the serum and PBMCs of canines treated with LUNAR-301 relative to control canines receiving only empty nanoparticles. Within the target PBMC population, canines receiving higher doses of LUNAR-301 had greater levels of miR-124 quantified, and the increases in miR-124 levels were sustained with multidosing. (B) Looking at the multidose study in greater resolution over the time course, miR-124 was quantified at doses 1, 4, 7, and 9. In the PBMC compartment, there was a dose accumulation effect with each subsequent dosing over the treatment period. (C) PBMCs were also isolated from fresh blood and evaluated for intracellular effector cytokine production. There appeared to be a dose-dependent response in the production of IL-2, TNF-a, and IFN-γ after LUNAR-301 treatment; the highest IFN-γ production was achieved with multidosing.
down signaling networks at multiple nodes along various pathways, including by alternative ligand activation. Therapeutic translation of miRs has been limited by technical challenges concerning delivery, miR stability, and avoidance of nonspecific immune responses. Endogenous miRs remain stable when secreted into the circulation if they are encapsulated in microvesicles, such as exosomes. 14 Although nanoparticles have been studied for over 40 years, it took decades to devise targeted nanoparticle therapies to deliver a drug cargo to tumors while sparing normal body cells from toxicity. One of the first was MyoCet-a liposomal nanoparticle containing doxorubicin for treatment of metastatic breast cancer. Several other nanoparticle chemotherapeutics have entered clinical trials, but to date, none have been devised to modulate the immune system. Most conventional immunotherapeutics have been limited to surface markers; consequently, nanoparticle delivery for intracellular immune targeting reported herein is a new approach (Fig. 6) . Our use of an immunomodulatory miR mimic as an active agent is also unique therapeutically. Prior approaches have included modified oligonucleotides designed to inhibit a given miR or oligonucleotides that act as aptamers to activate toll-like receptor signaling. Closer to our approach strategically is the use of synthetic miR mimics as replacement therapies, but these have been targeted to diseases (and cancers) of the liver, given preferential nanoparticle delivery to the liver during clearance from the blood. The much greater challenge in using miRs formulated with nanoparticles is to treat solid malignancies, and especially tumors within the CNS, a limitation overcome currently by exploiting the immune system to mediate the antitumor immune effects. Additionally, LUNAR nanoparticles have several advantages over other industry initiatives, including: (i) higher maximally tolerated dose; (ii) long-term stability (>4 mo) with no variation in particle size; (iii) lack of nonspecific immunogenicity; and (iv) biodegradability without accumulation after multiple dosing. Relative to our prior approach of using miR-124 with Lipofectamine in vivo, which can't be administered to human subjects and is insufficiently scalable, nanoparticles have been shown to have enhanced delivery of siRNA or miRNA relative to commercially available transfection reagents. 15, 16 Furthermore, another group has now recently demonstrated that polyethylene glycol lipid nanocapsules, constituents similar to LUNAR-301, are superior for delivery, viability, and lack of nonspecific immune activation to T cells and monocytes. 17 We have shown the feasibility of using miR-encapsulated lipid nanoparticles to reverse tumor-mediated immune suppression and prolong survival in a murine glioma model system by regulating the intracellular signaling pathway, STAT3. Of the multiple nanoparticle formulations tested, LUNAR-301 performed the best with the greatest survival prolongation of up to 60% of long-term surviving mice after a single treatment regimen. As expected, the nanoparticles accumulate in the liver, given that their primary mechanism of elimination is via the reticuloendothelial system. However, with a lipid linker molecule optimized 
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for biodegradability, our lipid nanoparticles degrade much faster than traditional lipid nanoparticles, with a half-life in the liver of less than 24 hours. This thereby prevents accumulation after multiple doses and reduces toxicity, as observed in both murine and non-tumor-bearing canine species. We can't completely exclude the possibility that there is nanoparticle tropism for other cell populations in vivo. However, in none of our experiments described herein did we see signs of systemic or microscopic toxicities on histopathologic examination of major organs at necropsy in multiple species. We suspect that since miR-124 is a natural, endogenous miR, with its function usually confined to neurons, excess does not regulate normal physiological processes outside the CNS, except in the setting of pathological perturbations such as cancer, with the associated upregulation of the STAT3 pathway. One could argue that by blocking STAT3 and thereby initiating immune activation, unintended autoimmunity could be triggered in the process. However, activated STAT3 has also been shown to have a role in autoimmunity, 18 and therefore the blockade of STAT3 may have clinical utility in this setting as well. This, along with the lack of finding any evidence of autoimmunity in mice monitored for over a year, including examination of the CNS, would indicate that LUNAR-301 does not have a high risk for inducing autoimmunity.
We took advantage of the intrinsic endocytic properties of immune cells to direct the miR to the immune compartment. [19] [20] [21] [22] Upon intravenous injection, LUNAR-301 would rapidly be accessible to these circulating immune cells. As expected, the nanoparticles were found to deliver their miR payload primarily to the monocyte/macrophage population (CD11b+), with lesser amounts delivered to the B-cell (CD19+) and T-cell (CD3+) compartments. The systemic delivery of LUNAR-301 influenced the trafficked antitumor immune responses, as reflected by decreases in STAT3 expression in the immune cells and decreases in T regulatory cells. We have shown that miR-124, the active agent of LUNAR-301, can alter the immunological responses within established intracerebral high-grade genetically engineered murine models of gliomas in a favorable manner, including by increasing trafficking of CD3+ T cells into the glioma microenvironment. 4, 9 This may have been achieved by the direct delivery of miR-124 to the T-cell compartment, secondarily through the modulation of the monocyte/macrophage compartment, or by a combination of both. Since there was only a several-fold increase of miR-124 within the T cells, the direct T-cell modulation mechanism seems less likely; however, the biological threshold for achieving translational inhibition of the STAT3 pathway has not yet been defined. Furthermore, we can't exclude the potential impact of miR-124 on the B cells in mediating a therapeutic effect. Notably, this approach may have therapeutic utility in the setting of lymphoma 23 because LUNAR-301 can potentially target STAT3 within B cells.
LUNAR-301 demonstrated the ability to protect against tumor recurrence. However, one limitation of our study was that we were unable to isolate the memory T cells to determine whether the response was primarily driven by a response from T central memory or T resident memory. Additionally, initial dose escalations of LUNAR-301 in canines and the delivery of miR-124 to the immune effector compartment suggest that allometric scaling may not apply, a phenomenon noted by others in the clearance of PEGylated liposomal anticancer agents. 24 The ability to scale the pharmacokinetic disposition of nanoparticle agents across species may be nanoparticle specific and model specific, and distinct methods of allometric scaling of nanoparticle agents relative to mononuclear compartments may need to be evaluated and developed. In summary, LUNAR-301 has the characteristics of a therapeutic agent, is safe in multiple species, and can be rapidly translated to glioma patients, because the murine, canine, and human sequence homology is almost 100% for miR-124.
